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An official in the Medicines 
Control Council (MCC)’s 
national law enforcement 
inspectorate and a Port 
Elizabeth district health 
manager have been suspended following an 
illegal trial of an unregistered Californian-
manufactured ‘immune-boosting’ spray on 
public sector clinic patients.
This was confirmed to Izindaba by both 
Ms Precious Matsoso, National Director-
General of Health, and the Registrar of 
the Medicines Control Council (MCC), Ms 
Mandisa Hela, who added that the local 
importers/distributors of Immutides Spray, 
Saulez Agencies CC, also face potential 
criminal charges.
A consignment of the spray, with an 
estimated value of nearly R1.4 million, 
was effectively impounded by the MCC 
four days before a second Eastern Cape 
health department-‘sanctioned’ 1 March 
‘trial’ involving 90 HIV/tuberculosis (TB) 
patients at the three main TB hospitals in 
the province was due to begin. The national 
health leadership duo rejected earnest 
claims by Saulez Agencies CC CEO Guy 
Saulez that he had met every application 
criterion pertaining at the time and merely 
followed official advice. Saulez said he took 
an MCC law enforcement ‘permission to 
sell’ document at face value and described 
a partially completed trial of Immutides 
Spray, plus the aborted prospective trial, as 
‘case studies, not medical trials’. Matsoso, 
herself a former MCC Registrar, said that 
any research involving medicines needed 
MCC approval (which Hela confirmed had 
not been sought). Hela reiterated that Saulez 
Agencies’ application for registration of 
Immutides as a complementary medicine 
had been turned down by both an MCC 
complementary medicines committee and 
an MCC veterinary committee, both citing 
‘genuine safety concerns’. She said the data 
collection sheets for Immutides Spray used at 
the Nelson Mandela Region’s primary health 
clinics made it a clinical trial, emphasising 
that ‘we don’t know what the protocol of 
the trial was, or even who the principal 
investigators were’. The first trial, at several 
municipal health clinics over a protracted 
period, preceded by several months a 
directive from the recently appointed Nelson 
Mandela Region’s District Health Manager, 
Dr Lulekwa Mayekiso. Mayekiso ordered 
all senior managers involved in caring for 
patients in the province’s three TB hospitals 
to dispense the spray to all patients – and 
issue scripts for it on discharge from hospital. 
Her edict, effective from 1 March this 
year, included a provision that the roll-out 
include the compilation and evaluation of a 
‘research report’ on Immutides. This project 
was halted four days before it was due to 
start after the Treatment Action Campaign 
(TAC) was tipped off by a concerned 
healthcare practitioner and fired off letters 
to the top provincial and national regulatory 
authorities. Eastern Cape Director-General 
of Health Dr Thobile Mbengashe confirmed 
that Mayekiso had been suspended on 
full pay in terms of the Public Service Act 
pending a disciplinary enquiry, expected to 
be complete by June. Mbengashe, who was 
head of the national HIV/AIDS department 
before taking his current post in September 
2013, said the enquiry would focus only on 
the directive Mayekiso issued in the face of 
an unregistered, unproven drug that had 
no ethical approval. The other provincial 
officials involved were not part of the 
enquiry, but he would not rule out that 
they might be. ‘The MCC and the NDoH 
[National Department of Health] have their 
own probes – we’re going with the strongest 
evidence we have.’ He said that neither 
Mrs Nomalanga Makwedini, at the time 
Eastern Cape Director-General for Clinical 
Management Services, nor Dr Francois 
Fourie, in charge of primary healthcare 
clinics in the Nelson Mandela Bay district, 
had ‘ordered anyone to use the drugs’.
While Izindaba has, independently of 
the MCC, established that the ‘immune-
boosting’ Immutides Spray remains scien-
tifically unproven, its distributor says he 
met every requirement health officials threw 
at him – and obtained what he thought 
was official permission to sell it. Documents 
supplied to Izindaba by Saulez, who admits 
having distributed the spray to thousands 
of people in the Eastern Cape, hoping to 
distribute it nationally, provide no evidence 
of efficacy, nor do they justify any clinical 
trials, according to a top pharmacologist 
we consulted. However, another set of 
documents Saulez supplied appear to support 
his contention that he followed all official 
advice and abided by regulatory requirements 
pertaining at the time. A possible fly in the 
ointment, Hela admits, is that she could find 
no record that Saulez Agencies was notified 
that their registration was turned down. 
‘But nothing stopped them from contacting 
us and enquiring as to the status of their 
application,’ she said.
It is possible that Saulez may have been 
given faulty advice – but virtually certain 
that approval of Immutides by national 
and provincial health officials was either 
fraudulent or deeply flawed. The legislative 
evolution included an obligatory 2002 ‘call-
up’ notice for complementary medicines 
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whereby importers and local manufacturers 
had to submit information to the MCC 
to enable a national audit of a chaotic 
market. However, this was replaced by 
a comprehensive set of stricter revisions 
promulgated in November 2013.
Prof. Andrew Gray, one of the country’s 
top pharmacologists and a senior lecturer 
in the subject at the School of Health 
Sciences at the Nelson Mandela School of 
Medicine, University of KwaZulu-Natal, said 
it was possible that Saulez Agencies was 
given contradictory advice by national and 
provincial officials. Gray, a research associate 
and consultant at the Centre for AIDS 
Programme of Research in South Africa 
(CAPRISA, based on his own campus), said 
that despite all protestations to the contrary, 
what was envisaged by Eastern Cape district 
health officials and Saulez Agencies CC was 
a clinical trial involving human subjects. 
No such trial could proceed without prior 
permission from the MCC, as well as from an 
accredited ethics committee. Not only were 
no data on the quality of Immutides Spray 
provided by the company, but the product 
was unregistered and the manufacturer 
had not demonstrated compliance with 
good manufacturing practices (one of the 
new requirements), as confirmed by a 
South African MCC inspection (the full 
scientific documentation on Immutides 
Spray as supplied by Saulez, with Professor 
Gray’s detailed analysis, is available upon 
request). The spray did not meet the 
updated requirements for registration as a 
complementary medicine. Gray said that 
one document provided by Saulez to back 
the efficacy of the spray was devoted to a 
description of the operation of the normal 
immune system, and then to laboratory, 
in vitro and animal studies conducted 
on transfer factor, various colostrum 
concentrates (ovine and bovine), proline-
rich polypeptides and lactoferrin. ‘While 
useful as background data, and establishing 
some degree of proof of concept, none can 
be considered as evidence of the efficacy 
or safety of the extract commercialised 
as Immutides Spray,’ he said. Hela said of 
Immutides’ bovine origin, ‘we could not 
even substantiate the claim on the protein 
they claimed’.
New broom meant to 
sweep snake-oils clean
Last year’s beefed-up complementary medi-
cine compliance regulations were an attempt 
to clean up the production, marketing and 
retailing of sub-standard complementary 
medicines, using amendments to over 20 
of the general regulations to improve public 
safety. From 15 November last year, any 
new complementary medicine entering 
the market had to be fully registered 
before going on sale to the public – with 
a ‘responsible pharmacist’ overseeing and 
taking responsibility for all processes within 
the manufacturing chain and submitting 
reports to the MCC and the Pharmacy 
Council. The regulations for products 
under the new definition of ‘complementary 
medicines’ (‘any substance or mixture of 
substances that originates from plants, 
minerals or animals; is used or intended to 
be used for, or manufactured or sold for use 
in assisting the innate healing power of a 
human being or animal to mitigate, modify, 
alleviate or prevent illness or the symptoms 
thereof or abnormal physical or mental state; 
and is used in accordance with the practice 
of the professions regulated under the Allied 
Health Professions Act, 1982 (Act No. 63 
of 1982)’) have now been structured on a 
benefit v. risk approach – which is significant 
in terms of looking at the facilities in which 
medicines are manufactured. 
Hela confirmed that a long-serving Ms 
Petra Bekker in the Inspectorate of Law 
Enforcement of the Pharmaceutical and 
Related Products Regulation Management 
Unit had signed an outdated form on an 
NDoH letterhead, granting permission for 
Immutides Spray to be ‘imported and sold as a 
complementary medicine in accordance with 
Government Gazette Notice 23128’. Bekker 
had been suspended pending an internal 
disciplinary hearing. She had gone ‘way 
beyond’ her delegated powers – using NDoH 
stationery instead of official MCC forms. 
Matsoso said her suspicions were aroused 
when she saw the NDoH letterhead. She had 
instructed Hela to begin an internal inquiry 
immediately. Hela confirmed that Bekker 
had been asked to handle the Immutides port 
clearance by a Port Elizabeth Port Health 
Authority official when the shipment first 
arrived. ‘What used to happen is our law 
enforcement officers had an arrangement 
with customs that anything not registered 
with the MCC that looks like a medicine, 
or is a suspicious cosmetic or such, will call 
them and clear out whether it’s for regulation 
or not. If the ingredients and claims look 
safe, the company is given a number and 
form under which the consignment can be 
released from the harbour to save them 
storage fees – that’s all.’ She emphasised 
that none of this could circumvent the legal 
requirement for MCC registration. ‘It looks 
like that when Saulez Agencies found out 
they were not coming right with the MCC, 
they were advised to work via Bekker.’
A hard-done-by Saulez said he had been 
‘put through the mill’ by the MCC’s law 
enforcement officers after complaints by the 
TAC, with ensuing widespread publicity over 
what appeared to be a cynical money-making 
scam. Saulez said that far from attempting to 
sidestep regulatory requirements, he had 
in 2011 met with the national Director of 
Nutrition, one Lynn Moeng, who advised 
him to register Immutides with the MCC. 
This had led to a meeting with the very 
law enforcement officers dispatched to 
the Eastern Cape by Matsoso in March to 
probe the aborted official provincial roll-
out. Added Saulez: ‘They (initially) told us 
what forms to fill in and how to go about 
things, recommending we hire a private 
medical consultant to submit all our product 
information.’ He provided Izindaba with a 
copy of his 17-page application to the MCC 
for registration of Immutides as a medicine, 
plus correspondence with Medreg, the 
private medical consultant that facilitated it. 
He also produced his non-surgical (ethical) 
request for a new NAPPI code and his 
NDoH ‘codification of supplier details’ 
report. (A NAPPI code is a unique identifier 
for a given ethical, surgical or consumable 
product which enables electronic transfer 
of information throughout the healthcare 
delivery chain.) Curiously, some eight 
months after submitting analysis sheets and 
samples to the MCC, Saulez received the 
Guy Saulez, CEO of Saulez Agencies CC.
She said the success of any 
provincial probe would 
‘depend on the political will’.
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now-suspect approval letter from its law 
enforcement inspectorate. On the strength 
of this, Makwedini issued an ‘acknowledge-
ment of approval’, confirming that Saulez 
Agencies CC had ‘applied to the NDoH for 
approval to register and supply Immutides 
Spray as a complementary medicine’. Saulez 
said he had genuinely believed that this 
cleared the way for a roll-out.
Immutides Spray widely 
used
‘We had also registered on the electronic 
suppliers databases of the Free State, 
Northern Cape and Western Cape,’ Saulez 
revealed. He disclosed that his company had 
sold ‘just under’ 5 000 bottles of Immutides 
Spray across the board ‘over about a year 
or so’ (one bottle lasts a single patient one 
month, taking four sprays in the morning 
and four in the evening), and claimed that 
an article in a top magazine for runners had 
resulted in numerous runners susceptible to 
colds and flu using the product before and 
after competitions, ‘with very good results 
– a lot of women were also giving it to their 
school children’, he added.
Saulez said Dr Fourie had told him that 
Immutides Spray was the only immune 
modulator he’d seen that actually supported 
the immune system. Fourie declined to 
speak to Izindaba, citing official media 
protocols and referring Izindaba to his 
senior, Dr Mayekiso. Saulez said Fourie 
and his pharmaceutical and therapeutic 
committee decided to issue the spray to 
‘certain groups of AIDS/TB coinfected 
patients with CD4 cell counts below 200 
who had already been on antiretroviral 
drugs for 12 months’. This was to be done 
by attaching the MCC law enforcement 
department ‘approval’ to the local directive 
signed by Dr Mayekiso.
‘I jumped through all 
the hoops’ – Saulez
Saulez said emails were sent to Lynn Moeng 
in Pretoria informing her of the decision, 
and that Moeng had asked to be kept abreast 
of developments – which she was. He said 
Fourie wanted to trial about 30 patients at 
each TB hospital, but the project was dropped 
like a hot potato upon the announcement of 
a criminal investigation (in terms of the 
Medicines Act and the Public Service Act). 
‘I said to the MCC law enforcement people 
when they arrived that their actions meant 
that Lynn Moeng, plus their own person 
who gave authorisation and Mrs Makwedini, 
had all made a mistake – and we were being 
punished! We’ve not put a foot wrong, but 
we’ve been absolutely castigated and our 
company name emblazoned all over the 
place … it’s not a scam, we’re not corrupt 
and there are no tenders involved,’ he said. 
Saulez said he accepted that the MCC had 
now made a ruling and that ‘as far as this 
product goes, it’s done in this country – 
under no circumstances may it be sold’. He 
added, ‘If Fourie had told us after six months 
that this is totally ineffective, we would have 
said fine, but we were really confident and he 
was excited – there was also the possibility 
of a national contract. Now I’m basically 
finished and all I want to do is clear my 
name.’ He denied any suggestion that his 
business partner, Mr Mike Xego, a former 
ANC chairperson of the Nelson Mandela 
Bay region and former provincial MP, used 
his name to gain any advantage. He said 
Immutides was not manufactured by Micro 
Basics in the USA (as reported by Izindaba), 
but in Arizona, and distributed to Saulez 
Agencies by Immutrition Inc. in San Diego, 
California. 
HIV clinician slams 
tardy controls
Professor Francois Venter, Deputy Executive 
Director at the Wits Reproductive Health 
and HIV Institute, said that, in general, ‘we 
repeatedly see snake-oil salespeople taking 
advantage of scared and confused patients, 
with (historically) little or no regulation 
or protection from the various agencies. 
Provincial health departments often seem 
to confuse things further by encouraging 
distribution. There are no short cuts for 
these supplements, especially now that many 
vitamin and other trials into so-called safe 
interventions affecting the immune system 
have actually demonstrated harm.’
Asked by Izindaba whether Makwedini 
would be included in the provincial 
probe and about her confidence in such 
an investigation, Hela referred us to the 
provincial Health MEC, Dr Mbengashe, 
whom she said she had instructed to ‘ensure 
it’s done by a competent authority’. She said 
the success of any provincial probe would 
‘depend on the political will’.
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‘I said to the MCC law 
enforcement people when they 
arrived that their actions meant 
that Lynn Moeng, plus their own 
person who gave authorisation 
and Mrs Makwedini, had all 
made a mistake – and we were 
being punished!’ – Guy Saulez
Prof. Andrew Gray, senior lecturer in pharma-
cology at the School of Health Sciences, Nelson 
Mandela School of Medicine, University of 
KwaZulu-Natal.
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